Summary
Global Markets Direct’s, ‘Diabetic Neuropathic Pain - Pipeline Review, H2 2016’, provides an overview of the Diabetic Neuropathic Pain pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Diabetic Neuropathic Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Neuropathic Pain and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Diabetic Neuropathic Pain
- The report reviews pipeline therapeutics for Diabetic Neuropathic Pain by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Diabetic Neuropathic Pain therapeutics and enlists all their major and minor projects
- The report assesses Diabetic Neuropathic Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Diabetic Neuropathic Pain
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Diabetic Neuropathic Pain
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Diabetic Neuropathic Pain pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
APT Therapeutics, Inc.
Astellas Pharma Inc.
BioDelivery Sciences International, Inc.
Bristol-Myers Squibb Company
Centrexion Therapeutics Corp
Chromocell Corporation
Daiichi Sankyo Company, Limited
Grunenthal GmbH
Hydra Biosciences, Inc.
Immune P
'
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Diabetic Neuropathic Pain Overview 9
Therapeutics Development 10
Pipeline Products for Diabetic Neuropathic Pain - Overview 10
Pipeline Products for Diabetic Neuropathic Pain - Comparative Analysis 11
Diabetic Neuropathic Pain - Therapeutics under Development by Companies 12
Diabetic Neuropathic Pain - Therapeutics under Investigation by Universities/Institutes 14
Diabetic Neuropathic Pain - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Diabetic Neuropathic Pain - Products under Development by Companies 18
Diabetic Neuropathic Pain - Products under Investigation by Universities/Institutes 19
Diabetic Neuropathic Pain - Companies Involved in Therapeutics Development 20
APT Therapeutics, Inc. 20
Astellas Pharma Inc. 21
BioDelivery Sciences International, Inc. 22
Bristol-Myers Squibb Company 23
Centrexion Therapeutics Corp 24
Chromocell Corporation 25
Daiichi Sankyo Company, Limited 26
Grunenthal GmbH 27
Hydra Biosciences, Inc. 28
Immune Pharmaceuticals Inc. 29
Laboratorios Del Dr. Esteve S.A. 30
Lohocla Research Corporation 31
Novaremed 32
PeriphaGen, Inc. 33
Pharmaleads SA 34
Prismic Pharmaceuticals, Inc. 35
Relmada Therapeutics, Inc. 36
Sphaera Pharma Pvt. Ltd. 37
Theravasc, Inc. 38
Diabetic Neuropathic Pain - Therapeutics Assessment 39
Assessment by Monotherapy Products 39
Assessment by Combination Products 40
Assessment by Target 41
Assessment by Mechanism of Action 43
Assessment by Route of Administration 45
Assessment by Molecule Type 47
Drug Profiles 49
(amitriptyline + ketamine hydrochloride) - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
(diclofenac sodium + triclocarban) - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
APT-102 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
AS-1069562 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
CC-8464 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
cebranopadol - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
clonidine hydrochloride - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
CNTX-6016 - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
EC-5026 - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
filgrastim - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
GERP-001 - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
HX-100 - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
Kindolor - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
mepivacaine hydrochloride - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
mirogabalin besylate - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
MR-309 - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
NRD-135SE1 - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
palmidrol - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
PGN-305 - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
PL-37 - Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
Small Molecule to Activate Kv7.2 for Neuropathic Pain - Drug Profile 79
Product Description 79
Mechanism Of Action 79
R&D Progress 79
sodium nitrite SR - Drug Profile 80
Product Description 80
Mechanism Of Action 80
R&D Progress 80
Diabetic Neuropathic Pain - Dormant Projects 82
Diabetic Neuropathic Pain - Discontinued Products 85
Diabetic Neuropathic Pain - Product Development Milestones 87
Featured News & Press Releases 87
Mar 04, 2016: BioDelivery Sciences to provide an update on Clonidine Topical Gel at the Cowen And Company 36th Annual Healthcare Conference and the 28th Annual Roth Conference 87
Jan 06, 2016: Hydra Biosciences to Present at the 8th Annual Biotech Showcase Conference in San Francisco on Jan. 11 87
Sep 28, 2015: Pharmaleads Announces the Opening of French Sites in Its International Phase IIa Clinical Study of PL37 87
Apr 22, 2015: Pharmaleads Announces the Inclusion of the First Patient in Phase IIa Study of Oral PL37 for Pain in Diabetic Neuropathy 88
Mar 30, 2015: BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development 89
Feb 04, 2015: Daiichi Sankyo Announces First Patients in Large-scale, Multi-national Phase 3 Clinical Programs for Mirogabalin 90
Dec 08, 2014: BioDelivery Sciences Announces Completion of Randomization in Phase 3 Trial of Clonidine Topical Gel for the Treatment of Painful Diabetic Neuropathy 91
Aug 06, 2014: BioDelivery Sciences Provides Update on Ongoing Phase 3 Pivotal Trial for Clonidine Topical Gel for Painful Diabetic Neuropathy 91
Oct 30, 2012: Drug Offers New Pain Management Therapy For Diabetics, Study Finds 91
Jun 04, 2012: EpiCept Receives Scientific Advice From EMA For AmiKet CIPN Program 92
Appendix 94
Methodology 94
Coverage 94
Secondary Research 94
Primary Research 94
Expert Panel Validation 94
Contact Us 94
Disclaimer 95
List of Tables
Number of Products under Development for Diabetic Neuropathic Pain, H2 2016 10
Number of Products under Development for Diabetic Neuropathic Pain - Comparative Analysis, H2 2016 11
Number of Products under Development by Companies, H2 2016 13
Number of Products under Investigation by Universities/Institutes, H2 2016 14
Comparative Analysis by Late Stage Development, H2 2016 15
Comparative Analysis by Clinical Stage Development, H2 2016 16
Comparative Analysis by Early Stage Development, H2 2016 17
Products under Development by Companies, H2 2016 18
Products under Investigation by Universities/Institutes, H2 2016 19
Diabetic Neuropathic Pain - Pipeline by APT Therapeutics, Inc., H2 2016 20
Diabetic Neuropathic Pain - Pipeline by Astellas Pharma Inc., H2 2016 21
Diabetic Neuropathic Pain - Pipeline by BioDelivery Sciences International, Inc., H2 2016 22
Diabetic Neuropathic Pain - Pipeline by Bristol-Myers Squibb Company, H2 2016 23
Diabetic Neuropathic Pain - Pipeline by Centrexion Therapeutics Corp, H2 2016 24
Diabetic Neuropathic Pain - Pipeline by Chromocell Corporation, H2 2016 25
Diabetic Neuropathic Pain - Pipeline by Daiichi Sankyo Company, Limited, H2 2016 26
Diabetic Neuropathic Pain - Pipeline by Grunenthal GmbH, H2 2016 27
Diabetic Neuropathic Pain - Pipeline by Hydra Biosciences, Inc., H2 2016 28
Diabetic Neuropathic Pain - Pipeline by Immune Pharmaceuticals Inc., H2 2016 29
Diabetic Neuropathic Pain - Pipeline by Laboratorios Del Dr. Esteve S.A., H2 2016 30
Diabetic Neuropathic Pain - Pipeline by Lohocla Research Corporation, H2 2016 31
Diabetic Neuropathic Pain - Pipeline by Novaremed, H2 2016 32
Diabetic Neuropathic Pain - Pipeline by PeriphaGen, Inc., H2 2016 33
Diabetic Neuropathic Pain - Pipeline by Pharmaleads SA, H2 2016 34
Diabetic Neuropathic Pain - Pipeline by Prismic Pharmaceuticals, Inc., H2 2016 35
Diabetic Neuropathic Pain - Pipeline by Relmada Therapeutics, Inc., H2 2016 36
Diabetic Neuropathic Pain - Pipeline by Sphaera Pharma Pvt. Ltd., H2 2016 37
Diabetic Neuropathic Pain - Pipeline by Theravasc, Inc., H2 2016 38
Assessment by Monotherapy Products, H2 2016 39
Assessment by Combination Products, H2 2016 40
Number of Products by Stage and Target, H2 2016 42
Number of Products by Stage and Mechanism of Action, H2 2016 44
Number of Products by Stage and Route of Administration, H2 2016 46
Number of Products by Stage and Molecule Type, H2 2016 48
Diabetic Neuropathic Pain - Dormant Projects, H2 2016 82
Diabetic Neuropathic Pain - Dormant Projects (Contd..1), H2 2016 83
Diabetic Neuropathic Pain - Dormant Projects (Contd..2), H2 2016 84
Diabetic Neuropathic Pain - Discontinued Products, H2 2016 85
Diabetic Neuropathic Pain - Discontinued Products (Contd..1), H2 2016 86
List of Figures
Number of Products under Development for Diabetic Neuropathic Pain, H2 2016 10
Number of Products under Development for Diabetic Neuropathic Pain - Comparative Analysis, H2 2016 11
Number of Products under Development by Companies, H2 2016 12
Comparative Analysis by Clinical Stage Development, H2 2016 16
Comparative Analysis by Early Stage Products, H2 2016 17
Assessment by Monotherapy Products, H2 2016 39
Number of Products by Top 10 Targets, H2 2016 41
Number of Products by Stage and Top 10 Targets, H2 2016 41
Number of Products by Top 10 Mechanism of Actions, H2 2016 43
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 43
Number of Products by Routes of Administration, H2 2016 45
Number of Products by Stage and Routes of Administration, H2 2016 45
Number of Products by Molecule Types, H2 2016 47
Number of Products by Stage and Molecule Types, H2 2016 47
